The FDA offers incentives for developing products that target life-threatening infections, and Astellas just became the latest drugmaker to take advantage. On Friday, the Japanese pharma bagged U.S. regulatory approval for Cresemba, an oral and injected antifungal that fights two rare but dangerous infections. More